Table 4.

A summary of in vivo efficacy of polymeric paclitaxel micelles and Taxol in mouse models.

Mice/Rats	Bearing cancer cells	Treatment	Administration	Dose (mg/kg)	Efficacy	Toxicity	Reference
Female BALB/c nude mice	Human colon HT-29 cancer	NK105	a single i.v. dose weekly for 3 weeks	25	Tumor suppression by both drugs increased in a dose-dependent manner. Superior antitumor acitivity compared with paclitaxel (P < 0.001). Tumor disappeared after the first dosing with NK105 at 100 mg/kg and all the mice remained tumor-free thereafter.	Less weight loss with NK105 compared with Taxol at the same given dose. Fewer degenerative myelinated fibers compared with paclitaxel (P < 0.001).	[24]
				50
				100
		Paclitaxel		25
				50
				100
Female BALB/c nude mice	Human ovarian SKOV-3 cancer	Genexol-PM	a single i.v. dose on days 0, 4, and 8	60	Significant inhibition of tumor relative to that in the paclitaxel treated mice.	No mice treated with Genexol- PM died during the experimental period.	[25]
		Paclitaxel		20
Tac:Cr:(NCr)-nu mice	Human breast MX-1 cancer	Genexol-PM	a single i.v. dose on days 0, 1, and 2	60	Significant inhibition of tumor relative to that in the paclitaxel treated mice. After 1 month, all the mice treated with Genexol-PM were tumor-free.	No mice treated with Genexol- PM died during the experimental period.
		Paclitaxel		20